Relapsed Refractory Multiple Myeloma Rrmm clinical trials

Explore recruiting relapsed refractory multiple myeloma rrmm clinical trials.

Recruiting relapsed refractory multiple myeloma rrmm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Multiple Myeloma Rrmm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Czechia, Greece, Germany, Poland, France, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Hungary, Italy, Netherlands, Poland, Spain, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

France, Norway, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)

Hungary, Belgium, Spain, Czechia, Italy, Greece

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma

Greece, Spain, Poland, Italy, Austria, Czechia +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsed Refractory Multiple Myeloma Rrmm trials by city

Relapsed Refractory Multiple Myeloma Rrmm in Toronto Relapsed Refractory Multiple Myeloma Rrmm in Vancouver Relapsed Refractory Multiple Myeloma Rrmm in Montreal Relapsed Refractory Multiple Myeloma Rrmm in Calgary Relapsed Refractory Multiple Myeloma Rrmm in Edmonton Relapsed Refractory Multiple Myeloma Rrmm in Ottawa Relapsed Refractory Multiple Myeloma Rrmm in Winnipeg Relapsed Refractory Multiple Myeloma Rrmm in Quebec City Relapsed Refractory Multiple Myeloma Rrmm in Hamilton Relapsed Refractory Multiple Myeloma Rrmm in Kitchener Relapsed Refractory Multiple Myeloma Rrmm in London Relapsed Refractory Multiple Myeloma Rrmm in Halifax Relapsed Refractory Multiple Myeloma Rrmm in New York Relapsed Refractory Multiple Myeloma Rrmm in Los Angeles Relapsed Refractory Multiple Myeloma Rrmm in Chicago Relapsed Refractory Multiple Myeloma Rrmm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease